IP Library Granted Patent US 9,598,693
Granted Patent B2
US 9,598,693 · App. 14/809,527 · Granted Mar 21, 2017

Oligomeric compounds and compositions for the use in modulation of micrornas

Inventors: Christine Esau (La Jolla, CA); Eric E. Swayze (Encinitas, CA); Balkrishen Bhat (Carlsbad, CA); Garth A. Kinberger (San Diego, CA)
Assignee: Ionis Pharmaceuticals, Inc.
C12N15/111C12N15/113C12N2310/11C12N2310/315C12N2310/321C12N2310/322C12N2310/3231C12N2310/341C12N2310/346C12N2320/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,693
App. No.
14/809,527
Granted
Mar 21, 2017
Kind
B2
Abstract

Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.

Claims (30)

1. An oligomeric compound comprising a contiguous sequence of nucleotides having the formula:

5′-MMmmMmMMMmmmmMMMMmmmmm-3′ or

5′-MMmMMmMMmMMmMMmMMmMMmMM-3′, wherein

M and m are each 2′-modified nucleosides, wherein the 2′-modified nucleosides of M and m are not the same.

2. The oligomeric compound of claim 1 , wherein

M is a 2′-MOE modified nucleoside and

m is a bicyclic sugar modified nucleoside.

3. The oligomeric compound of claim 1 , wherein

M is a 2′-MOE modified nucleoside,

m is a bicyclic sugar modified nucleoside having a 4′-(CH 2 ) n —O-2′ bridge, and

n is 1 or 2.

4. The oligomeric compound of claim 1 , wherein

M is a 2′-MOE modified nucleoside and

m is a 2′-F modified nucleoside.

5. The oligomeric compound of claim 1 , wherein

M is a 2′-OMe modified nucleoside and

m is a 2′-F modified nucleoside.

6. The oligomeric compound of claim 1 , wherein M is a 2′-modified nucleoside that comprises a 2′-substituent group selected from O—C 1 -C 12 alkyl, substituted O—C 1 -C 12 alkyl, O—C 2 -C 12 alkenyl, substituted O—C 2 -C 12 alkenyl, O—C 2 -C 12 alkynyl, substituted O—C 2 -C 12 alkynyl, amino, substituted amino, amide, substituted amide, aralkyl, substituted aralkyl, O-aralkyl, substituted O-aralkyl, N 3 , SH, CN, OCN, CF 3 , OCF 3 , SOCH 3 , —SO 2 CH 3 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino and polyalkylamino; and

wherein each substituent group is, independently, halogen, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, O—C 1 -C 12 alkyl, substituted O—C 1 -C 12 alkyl, S—C 1 -C 12 alkyl, substituted S—C 1 -C 12 alkyl, acyl (C(═O)—H), substituted acyl, amino, substituted amino, amide, substituted amide, C 1 -C 12 alkylamino, substituted C 1 -C 12 alkylamino, C 1 -C 12 aminoalkoxy, substituted C 1 -C 12 aminoalkoxy, C 1 -C 12 alkylaminooxy, substituted C 1 -C 12 alkylaminooxy, guanidinyl, substituted guanidinyl or a protecting group.

7. The oligomeric compound of claim 6 wherein M is a 2′-modified nucleoside that independently comprises a 2′-substituent group selected from O(CH 2 ) 0-2 CH 3 , O(CH 2 ) 2 OCH 3 , O(CH 2 ) 2 SCH 3 , OCH 2 C(H)CH 2 , O(CH 2 ) 2 ON(CH 3 ) 2 and OCH 2 C(═O)N(H)CH 3 .

8. The oligomeric compound of claim 7 , wherein m is a bicyclic sugar modified nucleoside.

9. The oligomeric compound of claim 7 , wherein m is a 2′-F modified nucleoside.

10. The oligomeric compound of claim 1 wherein m is a bicyclic sugar modified nucleoside that independently comprises a bridge group between the 2′ and the 4′-carbon atoms comprising from 1 to 8 linked biradical groups independently selected from —O—, —S—, —N(R 1 )—, —C(R 1 )(R 2 )—, —C(R 1 )═C(R 1 )—, —C(═NR 1 )—, —S(═O) 2 —, —S(═O)—, —C(═O)— and —C(═S)—;

each R 1 and R 2 is, independently, H, hydroxyl, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, a heterocycle radical, a substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5 -C 7 alicyclic radical, substituted C 5 -C 7 alicyclic radical, halogen, substituted oxy (—O—), amino, substituted amino, azido, carboxyl, substituted carboxyl, acyl, substituted acyl, CN, thiol, substituted thiol, sulfonyl (S(═O) 2 —H), substituted sulfonyl, sulfoxyl (S(═O)—H) or substituted sulfoxyl; and

wherein each substituent group is, independently, halogen, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, amino, substituted amino, acyl, substituted acyl, C 1 -C 12 aminoalkyl, C 1 -C 12 aminoalkoxy, substituted C 1 -C 12 aminoalkyl, substituted C 1 -C 12 aminoalkoxy or a protecting group.

11. The oligomeric compound of claim 10 , wherein M is a 2′-MOE modified nucleoside.

12. The oligomeric compound of claim 1 , wherein M is a 2′-F modified nucleoside.

13. The oligomeric compound of claim 12 , wherein M is a bicyclic sugar modified nucleoside.

14. The oligomeric compound of claim 1 , comprising at least one phosphorothioate internucleoside linkage group.

15. The oligomeric compound of claim 14 , wherein each internucleoside linkage group is a phosphorothioate internucleoside linkage group.

Assignments (1)
CHANGE OF NAME Recorded Feb 23, 2016
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 037893/0423 →
Continuity (5)
Continuation 13353114 · Jan 18, 2012
Continuation 12161286
Provisional Application 60762721 · Jan 27, 2006
Provisional Application 60805204 · Jun 19, 2006
Related Publication 20150322436A1 · Nov 12, 2015